Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study.

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.

IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies L. Lee Dupuis, Cathryn Sibbald,

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen– Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up.

Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma

Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program John P. Miller, Elizabeth H. Perry, Thomas H.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population by Sumithira Vasu,

Allogeneic Stem Cell Transplantation in Myelofibrosis

National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants Robert A. Bray, Carolyn K. Hurley, Naynesh.

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.

Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program Chatchada Karanes,

Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction Lucie M. Turcotte, Ashley.

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Navneet S. Majhail, Elizabeth A. Murphy, Nancy A

Betty T. Tran, Abigail Halperin, Jason W. Chien

High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study Parinda.

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai,

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Mats Remberger, Johan Törlén, Olle.

B Cells and Transplantation: An Educational Resource

Folinic Acid Supplementation in Higher Doses is Associated with Graft Rejection in Pediatric Hematopoietic Stem Cell Transplantation Henric Lindqvist,

High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem.

Joseph Pidala, Stephanie J

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

Mobilization of Hematopoietic Stem Cells with Lenograstim in Healthy Donors: Efficacy and Safety Analysis According to Donor Age Massimo Martino, Erminio.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses.

High-Resolution Match Rate of 7/8 and 9/10 or Better for the Be The Match Unrelated Donor Registry Kelly Buck, Kim Wadsworth, Michelle Setterholm, Martin.

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Biology of Blood and Marrow Transplantation

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor– Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation Dong.

A Randomized Controlled Trial to Compare Once- versus Twice-Daily Filgrastim for Mobilization of Peripheral Blood Stem Cells from Healthy Donors Yukiko.

Karen K. Ballen, Roberta J. King, Pintip Chitphakdithai, Charles D

Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value–Tailored Approach

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation Filippo Milano, Shelly Heimfeld, Ted Gooley,

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Optimal Donor Selection: Beyond HLA

Presentation transcript:

Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program Charles D. Bolan, Robert J. Hartzman, Elizabeth H. Perry, Lance Trainor, John Miller, Rebecca Miller, Lori Hanley, Pintip Chitphakdithai, Roberta J. King Biology of Blood and Marrow Transplantation Volume 14, Issue 9, Pages 23-28 (September 2008) DOI: 10.1016/j.bbmt.2008.06.001 Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Number of subsequent (second, third, fourth) NMDP-facilitated transplants, by transplant year. Biology of Blood and Marrow Transplantation 2008 14, 23-28DOI: (10.1016/j.bbmt.2008.06.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Placement of central lines according to anatomic location for donors undergoing 1-day and 2-day PBSC collections in male and female donors. For donors scheduled for a 1-day collection, the frequency of central line placement was similar in the internal jugular and femoral locations, each of which occurred more than twice as frequently as placement in subclavian or other locations. In contrast, the frequency of femoral line placement was less common, whereas the frequency of internal jugular and subclavian vein placement was more common in donors scheduled to undergo a 2-day collection. Biology of Blood and Marrow Transplantation 2008 14, 23-28DOI: (10.1016/j.bbmt.2008.06.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Frequency of male and female donors receiving central venous catheter placement, by year of collection. The rate of line placement has remained stable since the year 2000 for both male and female donors, at between 18% and 24% for females, and between 2% and 5% for males. Biology of Blood and Marrow Transplantation 2008 14, 23-28DOI: (10.1016/j.bbmt.2008.06.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Peripheral blood CD34+ cell counts in female and male donors following administration of filgrastim subcutaneously for 5 days at a targeted dose of 10 to 12 μg/kg/day. In both female and male donors, the CD34+ cell count increased with increasing donor weight (higher total amounts of filgrastim). Higher responses were also observed in male compared to female donors with body weights of <80 kg. Biology of Blood and Marrow Transplantation 2008 14, 23-28DOI: (10.1016/j.bbmt.2008.06.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Apheresis PBSC collection efficiency, plotted as the CD34+ cell yield per liter, processed versus the CD34+ cell concentration in peripheral blood at the beginning of apheresis. The product yield was highly correlated with the pre-apheresis CD34+ cell count. The collection efficiency was 38%, indicating that the product yield increased by 0.38 × 106/L processed for every 1 × 106 cell/L increase in the pre-apheresis CD34+ concentration. Biology of Blood and Marrow Transplantation 2008 14, 23-28DOI: (10.1016/j.bbmt.2008.06.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions